Compare FLNC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNC | URGN |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2021 | 2016 |
| Metric | FLNC | URGN |
|---|---|---|
| Price | $15.20 | $43.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 7 |
| Target Price | $15.71 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 8.8M | 692.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,262,830,000.00 | $1,128,000.00 |
| Revenue This Year | $51.23 | $129.09 |
| Revenue Next Year | $21.30 | $70.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.60 | $15.86 |
| 52 Week High | $33.51 | $43.93 |
| Indicator | FLNC | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 80.04 |
| Support Level | $14.28 | $17.89 |
| Resistance Level | $16.40 | N/A |
| Average True Range (ATR) | 1.38 | 2.14 |
| MACD | -0.19 | 0.14 |
| Stochastic Oscillator | 27.43 | 97.16 |
Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.